Testosterone Enanthate Non-Responder Profile: Who Doesn't Respond and Why

Who is testosterone enanthate approved for?

For testosterone replacement in men, intramuscular testosterone enanthate is indicated for low testosterone caused by testicular failure, or by a pituitary or hypothalamic disorder such as gonadotropin or luteinizing hormone-releasing hormone deficiency, or pituitary or hypothalamic injury from tumor, trauma or radiation [3]. The same label also lists delayed puberty in carefully selected boys and, secondarily, metastatic breast cancer in postmenopausal women [3].

The label states that safety and efficacy in age-related hypogonadism have not been established [3], and FDA says none of the approved testosterone products is approved for low testosterone without an associated medical condition [4]. In June 2026 FDA asked for that limitation to be removed from testosterone labels [4]; the enanthate label checked still carried the old text [3]. The label says to confirm hypogonadism before treatment with morning serum testosterone measured on at least two separate days, both below the normal range [3].

What the trials measured

A 2016 trial assigned 790 men aged 65 and older with testosterone below 275 ng/dL to testosterone gel or placebo gel for one year [2]. Sexual activity, sexual desire and erectile function improved. A vitality and fatigue score did not, and walking distance improved only when all three sub-trials were pooled, 20.5 percent versus 12.6 percent [2]. That trial did not test injectable enanthate.

Enanthate itself was tested in 61 healthy young men aged 18 to 35 whose own testosterone production was suppressed with a gonadotropin-releasing hormone agonist, then given weekly injections of 25, 50, 125, 300 or 600 mg for 20 weeks [1]. Fat-free mass rose with dose in the 125, 300 and 600 mg groups, by 3.4, 5.2 and 7.9 kg respectively. Changes in muscle size, leg strength, hemoglobin and IGF-I tracked testosterone concentrations, while fat mass and HDL cholesterol moved in the opposite direction [1]. Sexual function, mood, visual-spatial cognition and PSA did not change significantly at any dose [1].

Those men did not have hypogonadism, so the study does not show how a man with low testosterone feels on treatment.

Dose, hematocrit and blood pressure

The label gives 50 to 400 mg every 2 to 4 weeks, states that in general total doses above 400 mg per month are not required, and notes that injections more often than every two weeks are rarely indicated [3].

A network meta-analysis of 29 placebo-controlled trials in 3,393 men found intramuscular enanthate and cypionate raised mean hematocrit by 4.0 percent versus placebo, 95 percent CI 2.9 to 5.1 [5]. FDA's February 2025 class-wide labeling action states that ambulatory blood pressure monitoring studies confirmed a blood pressure increase with all testosterone products [6], and the enanthate label warns that testosterone can raise blood pressure and that these products are not recommended in uncontrolled hypertension [3].